

Resource Summary Report

Generated by ASWG on Aug 15, 2026

CD8 (SP16) Rabbit Monoclonal Antibody

RRID:AB_2892088

Type: Antibody

Proper Citation

Cell Marque Cat# 108R, RRID:AB_2892088

Antibody Information

URL: http://antibodyregistry.org/AB_2892088

Proper Citation: Cell Marque Cat# 108R, RRID:AB_2892088

Target Antigen: CD8

Host Organism: rabbit

Clonality: monoclonal

Antibody Name: CD8 (SP16) Rabbit Monoclonal Antibody

Description: This monoclonal targets CD8

Target Organism: human

Clone ID: SP16

Antibody ID: AB_2892088

Vendor: Cell Marque

Catalog Number: 108R

Alternative Catalog Numbers: 108R-14, 108R-16, 108R-15, 108R-18, 108R-17

Record Creation Time: 20250819T235607+0000

Record Last Update: 20250820T065224+0000

Ratings and Alerts

No rating or validation information has been found for CD8 (SP16) Rabbit Monoclonal Antibody.

No alerts have been found for CD8 (SP16) Rabbit Monoclonal Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Wu Q, et al. (2026) Myeloid-derived PD-L1 characterizes spatially organized immune architecture in colorectal cancer. *Frontiers in immunology*, 17, 1763068.

van der Elst A, et al. (2026) Molecular and Immune Landscape of Recurrent and/or Distant Metastatic Squamous Cell Carcinoma of the Head and Neck: An EORTC/IMMUCAN Project. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(13), 2732.

Baez E, et al. (2025) Oral Roflumilast Suppresses Proinflammatory Cytokine Signaling and Reduces CD4+ T-Cell and Neutrophil Infiltration in Psoriasis. *The Journal of investigative dermatology*.

Wilmott JS, et al. (2023) Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(3), 521.

Newell F, et al. (2022) Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. *Cancer cell*, 40(1), 88.

Knochelmann HM, et al. (2021) Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. *Cell reports. Medicine*, 2(10), 100426.